^
Association details:
| Biomarker: | FGFR2b positive |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | bemarituzumab (AMG 552) (FGFR2b inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).
Published date:
05/19/2021
Excerpt:
...for the subset of pts with ≥10% FGFR2b+ by IHC, the median OS for bema was 25.4 mo (95%CI: 13.8, not reached) vs 11.1 mo (95% CI: 8.4, 13.8) for placebo (HR: 0.41 95%CI: 0.23, 0.74)...The addition of bema to mFOLFOX6 improved the OS of 1L FGFR2b+ GC pts vs mFOLFOX6 alone.
Secondary therapy:
Modified FOLFOX6
DOI:
10.1200/JCO.2021.39.15_suppl.4010
Trial ID:
